Octapharma Gains Multiple FDA Approvals for WILATE Across Expanded VWD and Hemophilia A Indications

A multi-year supplemental BLA record for Octapharma's WILATE (von Willebrand Factor/Coagulation Factor VIII Complex, Human; STN: BL 125251) illustrates how plasma-derived biologics manufacturers navigate iterative indication expansions under FDA's Center for Biologics Evaluation and Research, a pathway with direct implications for QA and regulatory teams managing post-approval lifecycle submissions.

WILATE now carries three distinct approved indications: routine prophylaxis to reduce bleeding frequency in patients with von Willebrand Disease (VWD); on-demand treatment and routine prophylaxis for adults and adolescents with hemophilia A; and treatment of spontaneous or trauma-induced bleeding episodes in patients with severe VWD, or mild-to-moderate VWD where desmopressin is known or suspected to be ineffective or contraindicated. Each indication reflects a discrete regulatory action, not a single broad label grant.

The approval history spans at least five discrete FDA actions between September 2019 and November 2024, with letters issued in September 2019, December 2023, January 2024, March 2024, and November 2024. Supporting documentation includes clinical reviews, clinical pharmacology reviews, and statistical review memos tied to specific supplement numbers, notably STN 125251/244, demonstrating the layered review burden associated with each supplemental submission cycle.

For regulatory affairs leads at plasma-derived biologics manufacturers, the WILATE record is a functional case study in managing concurrent and sequential sBLA submissions without disrupting the approved product's manufacturing and distribution continuity. Each supplement requires its own clinical pharmacology and statistical review package, and the compressed cadence of approvals across 2023 and 2024 suggests active agency engagement on multiple open supplements simultaneously.

QA directors should note that each approval letter resets compliance obligations for the affected indication, including labeling controls, post-marketing commitments, and any manufacturing changes tied to the supplement. Under 21 CFR Part 600 and applicable biologics GMP standards, changes introduced through a supplement must be reflected in validated processes and current batch records before commercial distribution of product bearing the updated label.

The November 8, 2024 approval letter represents the most recent action on record, with the full supporting document set, including older materials predating the three-year public posting window, available through FDA's biologics approval database.

Manufacturers tracking their own supplemental BLA timelines against the WILATE precedent should benchmark the agency's review cadence for plasma-derived coagulation factor products, particularly where indication expansions involve pediatric or prophylaxis-specific endpoints that typically require dedicated statistical review memos.